Eight weeks between each HIV treatment? GSK notches PhIII win as it chases OK for long-acting regimen
GSK has cleared another test in its grand plan to topple Gilead’s HIV dominance by offering alternative treatments that consist of fewer drugs and last longer. A year after scoring positive Phase III data on a four-week course of cabotegravir and rilpivirine, its ViiV subsidiary now says that an eight-week regimen seem to work just as well.
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 65,800+ biopharma pros reading Endpoints daily — and it's free.